909 Healthcare, Inc., a client of Carl Meyer and The Wetrich Group, announced the release of the CoV19 prognostic screening tool.
CoV19 is a probability assessment that provides early and accurate evaluation of an individual’s likelihood of contracting active COVID-19 and differentiates between influenza and influenza-like illnesses for both symptomatic and asymptomatic individuals.
In collaboration with George Mason University, 909 Healthcare was created to develop and offer, free of charge, an evidenced-based prognostic screening tool for COVID-19 to assist healthcare systems, suppliers, and employers in other industries to resume business operations more safely.
The company said that the tool has a predictive accuracy rate of 79%. 909 Healthcare is launching its CoV19 prognostic screening tool for use with both symptomatic and asymptomatic individuals.